Lobbying Update: $1,170,000 of TENET HEALTHCARE CORPORATION lobbying was just disclosed

$1,170,000 of TENET HEALTHCARE CORPORATION lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.

This included lobbying on issues like:

"Hospital and physician payments under Medicare and Medicaid, general. Medicare/ Medicaid Reform- (Bundling of Medicare acute and post-acute hospital payments, payments for readmissions, value-based purchasing, physician self-referral)- Implementation of the Health Care and Education Reconciliation Act of 2012 (Pub. Law 111-143). Medicare site neutral payments Federal exchange subsidies under The Affordable Care Act Medicare and Medicaid Disproportionate Share Hospital funding Accountable Care Organization (ACO) programs CHGME ACA Stabilization Price Transparency Save the DA Act Telehealth 340B Medicare payment policy: IPPS/OPPS Graduate Medical Education (GME) Outpatient Surgery Quality and Access Act Medicaid Fiscal Accountability Regulation (MFAR) ACA premium tax credits Hospital and physician payments under Medicare and Medicaid, general. Medicare/ Medicaid Reform- (Bundling of Medicare acute and post-acute hospital payments, payments for readmissions, value-based purchasing, physician self-referral)- Implementation of the Health Care and Education Reconciliation Act of 2012 (Pub. Law 111-143). Medicare site neutral payments Federal exchange subsidies under The Affordable Care Act Medicare and Medicaid Disproportionate Share Hospital funding Accountable Care Organization (ACO) programs CHGME ACA Stabilization Price Transparency Telehealth 340B Medicare payment policy: IPPS/OPPS Graduate Medical Education (GME) Outpatient Surgery Quality and Access Act Medicaid Fiscal Accountability Regulation (MFAR) ACA premium tax credits House and Senate Budgets as pertain to Medicare and Medicaid. Consumer Financial Protection Bureau Rulemaking Tax Reform FTC non-compete rulemaking"

You can find more data on corporate lobbying on Quiver Quantitative.

THC Congressional Stock Trading

Members of Congress have traded $THC stock 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $THC stock by members of Congress over the last 6 months:

REPRESENTATIVE JONATHAN L. JACKSON has traded it 2 times. They made 2 purchases worth up to $65,000 on 12/10, 09/03 and 0 sales.
REPRESENTATIVE LISA C. MCCLAIN sold up to $15,000 on 08/04.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.

THC Insider Trading Activity

THC insiders have traded $THC stock on the open market 16 times in the past 6 months. Of those trades, 0 have been purchases and 16 have been sales.

Here’s a breakdown of recent trading of $THC stock by insiders over the last 6 months:

SAUMYA SUTARIA (CEO) has made 0 purchases and 2 sales selling 78,762 shares for an estimated $15,026,139.
TAMMY ROMO has made 0 purchases and 6 sales selling 27,500 shares for an estimated $5,563,324.
R. SCOTT RAMSEY (Principal Accounting Officer) has made 0 purchases and 3 sales selling 13,322 shares for an estimated $2,732,438.
LISA Y FOO (EVP, Chief Operating Officer) sold 8,000 shares for an estimated $1,436,240
CHRISTOPHER S. LYNCH has made 0 purchases and 2 sales selling 3,960 shares for an estimated $698,560.
RICHARD W FISHER sold 2,500 shares for an estimated $521,075
NADJA WEST sold 2,178 shares for an estimated $430,089

To track insider transactions, check out Quiver Quantitative's insider trading dashboard.

THC Hedge Fund Activity

We have seen 321 institutional investors add shares of THC stock to their portfolio, and 331 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

EMINENCE CAPITAL, LP added 1,109,450 shares (+inf%) to their portfolio in Q3 2025, for an estimated $225,262,728
BOSTON PARTNERS added 889,283 shares (+39.4%) to their portfolio in Q3 2025, for an estimated $180,560,020
CITADEL ADVISORS LLC removed 772,360 shares (-42.2%) from their portfolio in Q3 2025, for an estimated $156,819,974
AQR CAPITAL MANAGEMENT LLC added 720,160 shares (+62.3%) to their portfolio in Q3 2025, for an estimated $146,221,286
INVESCO LTD. removed 681,050 shares (-24.3%) from their portfolio in Q3 2025, for an estimated $138,280,392
GLENVIEW CAPITAL MANAGEMENT, LLC removed 606,326 shares (-20.7%) from their portfolio in Q3 2025, for an estimated $123,108,431
HOLOCENE ADVISORS, LP removed 584,404 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $118,657,388

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

THC Analyst Ratings

Wall Street analysts have issued reports on $THC in the last several months. We have seen 11 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Wells Fargo issued a "Overweight" rating on 01/07/2026
Barclays issued a "Overweight" rating on 11/21/2025
JP Morgan issued a "Overweight" rating on 11/13/2025
RBC Capital issued a "Outperform" rating on 10/30/2025
UBS issued a "Buy" rating on 10/29/2025
Cantor Fitzgerald issued a "Overweight" rating on 10/29/2025
Guggenheim issued a "Buy" rating on 10/29/2025

To track analyst ratings and price targets for THC, check out Quiver Quantitative's $THC forecast page.

THC Price Targets

Multiple analysts have issued price targets for $THC recently. We have seen 14 analysts offer price targets for $THC in the last 6 months, with a median target of $230.0.

Here are some recent targets:

Stephen Baxter from Wells Fargo set a target price of $229.0 on 01/07/2026
Ryan Langston from TD Cowen set a target price of $230.0 on 01/07/2026
Jason Cassorla from Guggenheim set a target price of $257.0 on 12/02/2025
Andrew Mok from Barclays set a target price of $240.0 on 11/21/2025
Benjamin Rossi from JP Morgan set a target price of $230.0 on 11/13/2025
David Macdonald from Truist Securities set a target price of $240.0 on 11/03/2025
Ben Hendrix from RBC Capital set a target price of $252.0 on 10/30/2025

This article is not financial advice. See Quiver Quantitative's disclaimers for more information.